Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim Hollingshead, President and Chief Executive Officer. “Omnipod 5 is the first and only automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes, following recent FDA clearance for the type 2 label indication. Insulet (PODD) leads the industry, and Omnipod 5 is revolutionizing diabetes care worldwide. I am proud of our team’s daily achievements in improving health outcomes and setting new standards in diabetes management.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Five Below downgraded, Snowflake upgraded: Wall Street’s top analyst calls
- Insulet initiated with an Outperform at Bernstein
- PODD Upcoming Earnings Report: What to Expect?
- Apple tested blood-sugar app, does not plan to release, Bloomberg says
- Insulet price target raised to $260 from $213 at Raymond James